Global Patent Index - EP 0949928 A4

EP 0949928 A4 2000-09-13 - ANDROGENIC AND BISPHOSPHONIC AGENTS COADMINISTERED TO TREAT DISEASES

Title (en)

ANDROGENIC AND BISPHOSPHONIC AGENTS COADMINISTERED TO TREAT DISEASES

Title (de)

ZUSAMMEN VERABREICHTE ANDROGENE UND DIPHOSPHONVERBINDUNGEN ZUR BEHANDLUNG VON KRANKHEITEN

Title (fr)

AGENTS ANDROGENE ET BISPHOSPHONIQUE COADMINISTRES POUR TRAITER DES MALADIES

Publication

EP 0949928 A4 (EN)

Application

EP 97949529 A

Priority

  • GB 9700697 A
  • US 9721306 W
  • US 3173496 P
  • US 3234196 P

Abstract (en)

[origin: WO9823274A1] The inhibition of natural bone formation experienced in the prophylaxis and/or treatment of bone resorption disease with a bisphosphonic acid or a pharmaceutically acceptable salt thereof is overcome by the concommitant administration of an androgenic agent.

IPC 1-7 (main, further and additional classification)

A61K 31/56; A61K 31/66

IPC 8 full level (invention and additional information)

A61K 31/568 (2006.01); A61K 31/66 (2006.01); A61K 31/663 (2006.01); A61P 3/14 (2006.01); A61P 19/08 (2006.01); A61P 19/10 (2006.01)

CPC (invention and additional information)

A61K 31/66 (2013.01)

Combination set (CPC)

  1. A61K 31/66 + A61K 31/565
  2. A61K 31/66 + A61K 2300/00

Citation (search report)

  • [XY] EP 0555845 A2 19930818 - MITSUBISHI CHEM IND [JP]
  • [Y] WO 9324128 A1 19931209 - MATTERN ET PARTNER PHARMAZEUTI [DE], et al
  • [Y] WO 9414455 A1 19940707 - MERCK & CO INC [US], et al
  • [Y] WO 9214474 A1 19920903 - NORWICH EATON PHARMA [US]
  • [Y] WANG, C. (1) ET AL: "Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men: A clinical research center study.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, (1996) VOL. 81, NO. 10, PP. 3654-3662., XP000916279
  • [Y] GLUECK, CHARLES J. (1) ET AL: "Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with stanozolol.", AMERICAN JOURNAL OF HEMATOLOGY, (1995) VOL. 48, NO. 4, PP. 213-220., XP000916283
  • [Y] REID, IAN R. (1) ET AL: "Glucocorticoid osteoporosis.", JOURNAL OF ASTHMA, (1994) VOL. 31, NO. 1, PP. 7-18., XP000916273
  • [Y] CHESTNUT, CHARLES H., III (1) ET AL: "Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling.", AMERICAN JOURNAL OF MEDICINE, (1995) VOL. 99, NO. 2, PP. 144-152., XP000916282
  • See also references of WO 9823274A1

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

EPO simple patent family

WO 9823274 A1 19980604; AU 7408698 A 19980622; AU 743121 B2 20020117; CA 2271664 A1 19980604; EP 0949928 A1 19991020; EP 0949928 A4 20000913; JP 2001507338 A 20010605

INPADOC legal status


2003-11-26 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20030513

2002-04-24 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20020307

2000-09-13 [A4] SUPPLEMENTARY SEARCH REPORT

- Effective date: 20000727

2000-09-13 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A4

- Designated State(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

1999-10-20 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 19990625

1999-10-20 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE